Werth Family Investment Associates

ChemWerth Inc. is the generic pharmaceutical company Peter J. Werth founded and operated, which generated the underlying wealth for the family office. While WFIA and ChemWerth are legally separate entities, the investment office's sector focus on life sciences and pharmaceuticals directly reflects the founder's operational expertise. Werth's industry relationships through ChemWerth likely serve as a proprietary sourcing channel for the family office's venture portfolio. The two entities share no formal cross-ownership structure that has been publicly disclosed.

Deal flow appears to come through two primary channels: the Connecticut life-science and technology ecosystem — particularly the frequent co-investment partnership with Connecticut Innovations — and Peter Werth's personal and professional network built through ChemWerth Inc. The office's consistent participation alongside Connecticut Innovations in portfolio companies like VeraDermics and Torigen suggests a relationship-driven sourcing model rather than a broad institutional process. There is no evidence of an open application portal or formal LP reporting structure.

All public evidence points to Werth Family Investment Associates operating exclusively as a single-family office, deploying Peter Werth's personal and family capital. The firm has not registered any pooled investment vehicle with the SEC and does not solicit third-party investors. Its co-investment activity with Connecticut Innovations involves parallel direct positions, not a commingled fund structure.

WFIA invests across the venture spectrum from seed to expansion and late-stage, though its confirmed positions lean toward early-stage and startup rounds. The office has backed pre-revenue biotech platforms and clinical-stage companies, suggesting comfort with long-duration scientific risk. Portfolio evidence indicates check sizes are likely at the angel-to-Series A scale, though no specific deployment range has been disclosed.

The Werth Family Foundation is the philanthropic arm operating alongside the investment office, with Peter Werth as the central figure in both. The foundation directs significant resources to the Bosnia & Herzegovina Futures Foundation, where Werth and Durić serve as mentors and donors. The investment committee and foundation board appear to share overlapping principals, though the foundation operates with independent grant-making governance. It also supports University of Connecticut initiatives, including the Werth Residence Tower on the Storrs campus.

Mušan Durić serves as Investment Portfolio Manager at WFIA, working directly with Peter Werth on investment decisions. Durić is also a central figure in the Bosnia & Herzegovina Futures Foundation, where his mentorship alongside Werth strengthens the talent pipeline linking the family office to the Balkans. His dual operational and philanthropic role makes him the most visible non-family investment professional in the firm's disclosed structure.

Connecticut Innovations, the state's strategic venture capital arm, has co-invested with WFIA in multiple Connecticut-based startups including VeraDermics and Torigen. The relationship appears to operate on a deal-by-deal basis rather than through a formal joint venture. This co-investment pattern anchors WFIA within the Connecticut innovation ecosystem and provides the family office with institutional-grade deal flow and diligence support for early-stage companies.